BrightGene Bio-Medical Technology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BrightGene Bio-Medical Technology Co., Ltd. - overview
Established
2001
Location
Suzhou, Jiangsu, China
Primary Industry
Pharmaceuticals
About
Established in 2001 and based in Suzhou, China, BrightGene Bio-Medical Technology Co. , Ltd. operates as an API and preparation developer that mainly provides original new drugs. In January 2019, it raised CNY 550 million of pre-IPO funding led by new investors HighLight Capital and Sequoia Capital.
In November 2019, BrightGene Bio-Medical Technology Co. , Ltd. was listed on the Shanghai Stock Exchange. The company mainly provides API and preparation drugs.
The product line covers multiple therapeutic areas such as antiviral, antifungal, immunosuppressive, anti-tumor, cardiovascular and cerebrovascular, respiratory, and iron supplements. Products include BGM0504 injection, entecavir, pimecrolimus, and micafungin sodium for injection. The company generates revenue by providing API and preparation drugs such as BGM0504 injection and entecavir.
Current Investors
Lilly Asia Ventures, Oriza Holdings, Suzhou International Development Venture Capital Holding
Primary Industry
Pharmaceuticals
Sub Industries
Biopolymers, Molecular Science, Genetics & Gene Therapy, Pharmaceuticals, Biomaterials
Website
www.bright-gene.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
BrightGene Bio-Medical Technology Co., Ltd. - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 200,924,791.1 | 316,770,478.7 | 407,503,282.6 | 503,081,661.8 | 783,713,150.7 | 1,052,408,590.9 | - | - | - |
| % Revenue Growth (YoY) | - | 57.7% | 28.6% | 23.5% | 55.8% | 34.3% | - | - | - |
| EBITDA (USD) | 45,333,700 | 73,853,900 | 106,742,600 | 151,841,760 | 237,017,149.6 | 293,171,402 | - | - | - |
| Operating Income (USD) | 15,913,611 | 49,193,665.9 | 81,844,453.8 | 118,464,994.5 | 197,776,992 | 258,991,106.2 | - | - | - |
| Operating Margin | 7.9% | 15.5% | 20.1% | 23.5% | 25.2% | 24.6% | - | - | - |
| % EBITDA Margin | 22.6% | 23.3% | 26.2% | 30.2% | 30.2% | 27.9% | - | - | - |
| NET Income (USD) | 17,060,972 | 45,876,431.5 | 73,202,041.2 | 111,083,322.8 | 169,361,909.3 | 237,557,816.8 | - | - | - |
| % Net Margin | 8.5% | 14.5% | 18.0% | 22.1% | 21.6% | 22.6% | - | - | - |
BrightGene Bio-Medical Technology Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Announced | Geekgene | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.